Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,121 to 2,140 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| BCG-vaccine vs Control Children: Atopic Dermatitis | 466 of 2,052 495 of 1,952 | -2.6 points -5.3 to -0.0 | 4,004 | NCT01694108 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. |
| Belimumab 10 mg/kg vs Placebo: Number of Deaths - On Treatment Period (Week 52) | 10 of 2,002 8 of 2,001 | 0.1 points -0.3 to 0.6 | 4,003 | NCT01705977 Belimumab Assessment of Safety in SLE |
| Belimumab 10 mg/kg vs Placebo: Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52) | 220 of 2,002 222 of 2,001 | -0.1 points -2.1 to 1.8 | 4,003 | NCT01705977 Belimumab Assessment of Safety in SLE |
| Belimumab 10 mg/kg vs Placebo: Number of Deaths Reported - On-study Period (Week 52) | 13 of 2,002 22 of 2,001 | -0.5 points -1.1 to 0.1 | 4,003 | NCT01705977 Belimumab Assessment of Safety in SLE |
| Belimumab 10 mg/kg vs Placebo: Number of Participants With SAEs Reported During On-study Period (Week 52) | 233 of 2,002 241 of 2,001 | -0.4 points -2.4 to 1.6 | 4,003 | NCT01705977 Belimumab Assessment of Safety in SLE |
| Belimumab 10 mg/kg vs Placebo: deaths from any cause | 51 of 2,002 80 of 2,001 | -1.5 points -2.6 to -0.3 | 4,003 | NCT01705977 Belimumab Assessment of Safety in SLE |
| Belimumab 10 mg/kg vs Placebo: serious adverse events | 233 of 2,002 241 of 2,001 | -0.4 points -2.4 to 1.6 | 4,003 | NCT01705977 Belimumab Assessment of Safety in SLE |
| Kidney Action Team Recommendations vs Usual Care: Percentage of Patients Who Receive Inpatient Dialysis | 31 of 1,999 30 of 2,004 | 0.1 points -0.7 to 0.8 | 4,003 | NCT04040296 Personalized Recommendations for Acute Kidney Injury (AKI) Care |
| Kidney Action Team Recommendations vs Usual Care: Percent of Patients Who Receive a Kidney Consult Within 14 Days | 321 of 1,999 284 of 2,004 | 1.9 points -0.3 to 4.1 | 4,003 | NCT04040296 Personalized Recommendations for Acute Kidney Injury (AKI) Care |
| Kidney Action Team Recommendations vs Usual Care: Percentage of Inpatient Mortality | 191 of 1,999 185 of 2,004 | 0.3 points -1.5 to 2.1 | 4,003 | NCT04040296 Personalized Recommendations for Acute Kidney Injury (AKI) Care |
| Kidney Action Team Recommendations vs Usual Care: Percentage of Patients With Progression of Acute Kidney Injury | 270 of 1,999 261 of 2,004 | 0.5 points -1.6 to 2.6 | 4,003 | NCT04040296 Personalized Recommendations for Acute Kidney Injury (AKI) Care |
| Kidney Action Team Recommendations vs Usual Care: Percent of Patients Who Are Discharged to Hospice Care 14 Days | 87 of 1,999 106 of 2,004 | -0.9 points -2.3 to 0.4 | 4,003 | NCT04040296 Personalized Recommendations for Acute Kidney Injury (AKI) Care |
| Kidney Action Team Recommendations vs Usual Care: Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death | 395 of 1,999 369 of 2,004 | 1.3 points -1.1 to 3.8 | 4,003 | NCT04040296 Personalized Recommendations for Acute Kidney Injury (AKI) Care |
| Kidney Action Team Recommendations vs Usual Care: deaths from any cause | 191 of 1,999 185 of 2,004 | 0.3 points -1.5 to 2.1 | 4,003 | NCT04040296 Personalized Recommendations for Acute Kidney Injury (AKI) Care |
| Trial Mailed FIT Intervention - Age Group 50-75 vs Trial Usual Care - Age Group 50-75: Proportion of Subjects Who Completed Colorectal Cancer (CRC) Screening Within 6 Months (Trial - Age Group 50-75) | 598 of 2,001 192 of 2,001 | 20.3 points 17.9 to 22.7 | 4,002 | NCT04406714 Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE) |
| FSC Cohort vs AC Cohort: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation | 200 of 1,078 674 of 2,923 | -4.5 points -7.2 to -1.7 | 4,001 | NCT01337336 Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population |
| CYD Dengue Vaccine Group vs Control Group: deaths from any cause | 1 of 2,666 4 of 1,331 | -0.3 points -0.7 to -0.0 | 3,997 | NCT00842530 Efficacy and Safety of Dengue Vaccine in Healthy Children |
| CYD Dengue Vaccine Group vs Control Group: serious adverse events | 315 of 2,666 176 of 1,331 | -1.4 points -3.7 to 0.7 | 3,997 | NCT00842530 Efficacy and Safety of Dengue Vaccine in Healthy Children |
| No Mobile Phone-administered Triage Tool vs Mobile Phone-administered Triage Tool: Proportion of Successful Contacts | 837 of 1,491 1,514 of 2,499 | -4.4 points -7.6 to -1.3 | 3,990 | NCT03805646 Mobile Phone-administered Triage Tool to Followup on Discharged Trauma Patients |
| No Mobile Phone-administered Triage Tool vs Mobile Phone-administered Triage Tool: deaths from any cause | 40 of 1,491 49 of 2,499 | 0.7 points -0.2 to 1.8 | 3,990 | NCT03805646 Mobile Phone-administered Triage Tool to Followup on Discharged Trauma Patients |
Code
curl "https://conductscience.org/api/comparisons/v1?page=107"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=107
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01694108-0f074784",
"title": "BCG-vaccine vs Control Children: Atopic Dermatitis",
"summary": "466 of 2052 against 495 of 1952; risk difference -2.6 points, 95% interval -5.3 to -0.0; NCT01694108, Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.",
"record": "/library/comparisons/NCT01694108-0f074784",
"nct_id": "NCT01694108",
"kind": "outcome",
"participants": 4004,
"risk_difference": {
"value": -0.026490549004569736,
"lower": -0.052965441717791314,
"upper": -0.000022907952555648037
},
"group_1": "466 of 2,052",
"group_2": "495 of 1,952",
"difference": "-2.6 points",
"interval": "-5.3 to -0.0",
"trial_title": "Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children."
},
{
"id": "NCT01705977-0baa05e4",
"title": "Belimumab 10 mg/kg vs Placebo: Number of Deaths - On Treatment Period (Week 52)",
"summary": "10 of 2002 against 8 of 2001; risk difference 0.1 points, 95% interval -0.3 to 0.6; NCT01705977, Belimumab Assessment of Safety in SLE",
"record": "/library/comparisons/NCT01705977-0baa05e4",
"nct_id": "NCT01705977",
"kind": "outcome",
"participants": 4003,
"risk_difference": {
"value": 0.0009970039955047453,
"lower": -0.0034957816189339222,
"upper": 0.005614266000875675
},
"group_1": "10 of 2,002",
"group_2": "8 of 2,001",
"difference": "0.1 points",
"interval": "-0.3 to 0.6",
"trial_title": "Belimumab Assessment of Safety in SLE"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=108",
"request_id": "unXPOdjgeiek4qPg"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant